2Buzdar AU.New generation aromatase inhitors-form the advanced to the adjuvant setting[J].Breast Cancer Res Treat,2002,75(Suppl 1):S13.
3Chung CT,Carlson RW.The role of aromatase inhibitors in early breast cancer[J].Curr Treat Options Oncol,2003,4(2):133.
4Aman Buzdar on behalf of the ATAC trialist's group.MD Anderson Cancer Centre,Houson,TX,USA.The ATAC trial in postmenopausal women with early breast cancer-updated effi-cacy results based on a median follow up of 47 months[J].Lancet,2002,359:2131.
5Dixson J M,Love CDB,Tucker S,et al.Letrozole as primary medical therapy for locally advanced and large operable breast cancer[J].Proc ASCO,1998,17:104.
6Bajetta E,Zilembo N,Guillevin L,et al.Endocrine trial comparing 0.5 and 2.5 mg of letrozole in postmenopausal patients with advanced breast cancer[J].Proc ASCO,1998,17:229.
7Bertelli G,Garrone O,Merlano M,et al.Sequential use of aromatse inactivators and inhitors and inhibitor in advanced breast cancer[J].Proc Am Soc Clin Oncol,2002,21:60a.
8Baum M,Budzar AU,Cuzick J,et al.Anastrozole alone or in combitination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomized trial[J].Lancet,2002,359(9324):2132.
10Bertelli G,Garrone 0.Merlano M,et al. Sequential use of aro-matse inactivators and inhitors and inhibitor in advanced breastcancerGX Proc Am Soc Clin Oncol, 2002,21 : 60-62.
